Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs

Current Medicinal Chemistry

Volumn 17, Issue 35, 2010, Pages 4270-4290

  Salerno, S ^a   Da Settimo, F ^a   Taliani, S ^a   Simorini, F ^a   La Motta, C ^a   Fornaciari, G ^a   Marini, A M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Anticancer drugs; Antiproliferative activity; Dual inhibitor; Topoisomerase I; Topoisomerase II

Indexed keywords

6 METHOXY 7,8 METHYLENDIOXYCOUMARIN; ANTINEOPLASTIC AGENT; APIGENIN; BATRACYLIN; CAMPTOTHECIN; CURCUMIN; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELOMOTECAN; EPICATECHIN; ETOPOSIDE; FISETIN; GYRASE INHIBITOR; MYRICETIN; OCTADECENOIC ACID; PACLITAXEL; PHENAZINE DERIVATIVE; PRODIGIOSIN; SCOPOLETIN; SITOGLUSIDE; TAFLUPOSIDE; TILIA AMURENSIS EXTRACT; TOPOTECAN; TRIPTYCENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XR 11576; XR 5944;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B CELL LEUKEMIA; BARK; BINDING AFFINITY; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; COLITIS; COLON ADENOCARCINOMA; COLON CANCER; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG BINDING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; FEBRILE NEUTROPENIA; HUMAN; IC 50; KIDNEY FAILURE; LEUKEMIA; LEUKEMIA CELL; LIVER CELL CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NONHUMAN; OVARY CANCER; PERIPHERAL EDEMA; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS;

EID: 78650670619     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793361252     Document Type: Article

References (181)

1. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer, 2005, 5, 876-885.
2. Champoux, J. J. in: DNA Topology and its Biological Effects. J. C. Wang and N. R. Cozzarelli Eds, Cold Spring Harbor, NY, 1990, 217-242.
3. Osheroff, N. DNA Topoisomerases. Biochim. Biophys. Acta, 1998, 1400, 1-2.
4. Champoux, J. J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70, 369-413.
5. Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol., 2002, 3, 430-440.
6. Stewart, L.; Redimbo, M. R.; Qiu, X.; Hol, W. G. J.; Champoux, J. J. A model for the mechanism of human topoisomerase I. Science, 1998, 279, 1534-1541.
7. Zhang, H.; Barcélo, J. M.; Lee, B.; Kohlhagen, G.; Zimonjic, D. B.; Popescu, N. C.; Pommier, Y. Human mitochondrial topoisomerase I. Proc. Natl Acad. Sci. USA, 2001, 98, 10608-10613.
8. Wang, J. C. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys., 1998, 31, 107-144.
9. Dong, K. C.; Berger, J. M. Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature, 2007, 450, 1201-1205.
10. Corbett, K. D.; Berger, J. M. Structure, molecular mechanisms and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct., 2004, 33, 95-118.
11. Berger, J. M.; Gambin, S. J.; Harrison, S. C.; Wang, J. C. Structure and mechanism of DNA topoisomerase II. Nature, 1996, 379, 225-232;
12. erratum: Nature, 1996, 380, 179.
13. Nittis, J. L. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer, 2009, 9, 327-337.
14. Holden, J. A. DNA topoisomerases as anticancer drug targets: from the laboratory to clinic. Curr. Med. Chem.-Anti-Cancer Agents, 2001, 1, 1-25.
15. Capranico, G.; Zunino, F. DNA topoisomerase-trapping antitumour drugs. Eur. J. Cancer, 1992, 28 A, 2055-2060.
16. Corbett, A. H.; Osheroff, N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol., 1993, 6, 585-597.
17. Pommier, Y. DNA Topoisomerase II inhibitors. In Cancer therapeutics: experimental and clinical agents, Teicher, B. A.; Ed. Totowa; NJ: Humana Press Inc.; 1997; pp. 153-174.
18. Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer, 2009, 9, 338-350.
19. Wilstermann, A. M.; Osheroff, N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem., 2003, 3, 321-338.
20. (a) Baldwin, E. L.; Osheroff, N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem.-Anti-Cancer Agents, 2005, 5, 363-372.
21. (b) Pommier, Y.; Marchand, C. Interfacial Inhibitors of Protein-Nucleic Acid Interactions. Curr. Med. Chem.-Anti-Cancer Agents, 2005, 5 (4), 421-429.
22. Capranico, G.; Giaccone, G.; Zunino, F.; Garattini, S.; D'Incalci, M. DNA topoisomerase II poisons and inhibitors. Cancer Chemother. Biol. Response Modif., 1997, 17, 114-131.
23. (a) Larsen, A. K.; Escargueil, A. E.; Skladanowski, A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Therap., 2003, 99 (2), 167-181.
24. (b) Classen, S.; Olland, S.; Berger, J. M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. PNAS, 2003, 100 (19), 10629-10634.
25. (c) Oblak, M.; Kotnik, M.; Solmajer, T. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr. Med. Chem., 2007, 14, 2033-2047.
26. Gatto, B.; Capranico, G.; Palumbo, M. Drugs acting on DNA topoisomerases: Recent avances and future perspectives. Curr. Pharm. Des., 1999, 5, 195-215.
27. Fortune, J. M.; Osheroff, N. Merbarone inhibits the catalytic activity of human topoisomerase II-alpha by blocking DNA cleavage. J. Biol. Chem. 1998, 273, 17643-17650.
28. (a) Andoh, T.; Ishida, R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta, 1998, 1400, 155-171.
29. (b) Jensen, L. H.; Nitiss, K. C.; Rose, A.; Dong, J.; Zhou, J.; Hu, T.; Osheroff, N.; Jensen, P. B.; Sehested, M.; Nitiss, J. L. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J. Biol. Chem., 2000, 275, 2137-2146.
30. (c) Huang, K. C.; Gao, H.; Yamasaki, E. F.; Grabowski, D. R.; Liu, S.; Shen; L. L.; Shan; K. K.; Ganapathi, R.; Snapka, R. M. Topoisomerase II poisoning by ICRF-193. J. Biol. Chem., 2001, 276, 44488-44494.
31. Pizzolato, J. F.; Saltz, L. B. The camptothecins. Lancet, 2003, 361, 2235-2242.
32. (a) Pommier, Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer, 2006, 6, 789-802.
33. (b) Bailly, C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit. Rev. Oncol. Hematol., 2003, 45 (1), 91-108.
34. (c) Demarquay, D.; Huchet, M.; Coulomb, H.; Lesueur-Ginot, L.; Lavergne, O.; Kasprzyk, P. G.; Bailly, C.; Camara, J.; Bigg, D. C. H.. The homocamptothecin BN80915 is a highly potent orally active topoisomerase I poison. Anticancer Drugs, 2001, 12, 9-19.
35. (d) Gelderblom, H.; Salazar, R.; Verweij, J.; Pentheroudakis, George; de Jonge, M. J. A.; Devlin, M.; van Hooije, C.; Seguy, F.; Obach, R.; Prunonosa, J.; Principe, P.; Twelves, C. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin. Cancer Res., 2003, 9 (11), 4101-7.
36. (e) Lansiaux, A.; Facompre, M.; Wattez, N., Hildebrand, M. P.; Bal, C.; Demarquay, D.; Lavergne, O.; Bigg, D. C. H.; Bailly, C. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells. Mol. Pharmacol., 2001, 60 (3), 450-61.
37. (f) Larsen, A. K.; Gilbert, C.; Chyzak, G.; Plisov, S. Y.; Naguibneva, I.; Lavergne, O.; Lesueur-Ginot, L.; Bigg, D. C. H. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res., 2001, 61 (7), 2961-2967.
38. (a) Long, B. H.; Balasubramanian, B. N. Non-camptothecin topoisomerase I active compounds as potential anticancer agents. Expert. Opin. Ther. Pat., 2000, 10, 635-666.
39. (b) Saif, M. W.; Diasio, R. B. Edotecarin: a novel topoisomerase I inhibitor. Clin. Colorectal Cancer, 2005, 5, 27-36.
40. (a) Felix, C. A. Secondary leukemias induced by topoisomerasetargeted drugs. Biochim. Biophys. Acta, 1998, 1400, 233-255.
41. (b) Mistry, A. R.; Felix, C. A.; Whitmarsh, R. J.; Mason, A. Reiter, A.; Cassinat, B.; Parry, A.; Walz, C.; Wiemels, J. L.; Segal, M. R.; Ades, L.; Blair, I. A.; Osheroff, N.; Peniket, A. J.; Lafage-Ochitaloff, M.; Cross, N. C. P.; Chomienne, C.; Solomon, E.; Fenaux, P.; Grimwade, D. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N. Engl. J. Med., 2005, 352, 1529-1538.
42. Azarova, A. M.; Lyu, Y.; Lin, C.; Tsai, Y.; Lau, J. Y.; Wang, J. C.; Liu, L. F. Roles of Topoisomerases II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA, 2007, 107, 11014-11019.
43. Bishop, T.; Sham, P. Analysis of Multifactorial Diseases; Academic Press: New York, 2000; pp 1-320.
44. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
45. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. J. Med. Chem. 2008, 51, 347-372.
46. Denny, W. A. Dual topoisomerase I/II poisons as anticancer drugs. Exp. Opin. Invest. Drugs, 1997, 6 (12), 1845-1851
47. Eder, J. P.; Chan, V.; Wong, J.; Wong, Y. W.; Ara, G.; Northey, D.; Rizvi, N.; Teicher, B. A. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother. Pharmacol., 1998, 42, 327-335.
48. Houghton, J. A.; Cheshire, P. J.; Hallman, J. D. II; Lutz, L.; Luo, X.; Li, Y.; Houghton, P. J. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin. Cancer Res., 1996, 2, 107-118.
49. Crump, M.; Lipton, J.; Hedley, D.; Sutton, D.; Shepherd, F.; Minden, M.; Stewart, K.; Beare, S.; Eisenhauer, E. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. Leukemia, 1999, 13, 343-347.
50. Vey, N.; Kantarjian, H.; Beran, M.; O'Brien, S.; Cortes, J.; Koller, C.; Estey, E. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Invest. New Drugs, 1999, 17, 89-95.
51. Simon, T., Langler, A., Berthold, F., Klingebiel, T. & Hero, B. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastomaresults of a phase 2 trial. J. Pediatr. Hematol. Oncol. 2007, 29, 101-106.
52. Choi, H. J., Cho, B. C.; Shin, S. J.; Cheon, S. H.; Jung, J. Y.; Chang, J.; Kim, S. K.; Sohn, J. H.; Kim, J. H. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum firstline chemotherapy. Cancer Chemother. Pharmacol., 2008, 61, 309-313.
53. Saraiya, B.; Gounder, M.; Dutta, J.; Saleem, A.; Collazo, C.; Zimmerman, L.; Nazar, A.; Gharibo, M.; Schaar, D.; Lin, Y.; Shih, W.; Aisner, J.; Strair, R. K.; Rubin, E. H. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs, 2008, 19, 411-420.
54. Denny, W. A.; Baguley, B. C. Dual topoisomerase I/II Inhibitors in Cancer Therapy. Curr. Topics Med. Chem., 2003, 3, 1349-1364.
55. Denny, W. A. Emerging DNA topoisomerase inhibitors as anticancer drugs. Exp. Opin. Emerg. Drugs, 2004, 9 (1), 105-133.
56. Perrin, D.; van Hille, B.; Barret, J. M.; Kruczynski, A.; Etievant, C.; Imbert, T.; Hill, B. T. F11782, a novel epipodophylloid nonintercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem. Pharmacol., 2000, 59, 807-819.
57. Barret, J. M.; Cadou, M.; Hill, B. T. Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F11782, a novel fluorinated epipodophylloid. Biochem. Pharmacol., 2002, 63, 251-258.
58. Kruczynski, A.; Etiévant, C.; Perrin, D.; Imbert, T.; Colpaert, F.; Hill, B. T. Preclinical antitumour activity of F11782, a novel dual catalytic inhibitor of topoisomerases. Br. J. Cancer, 2000, 83, 1516-1524.
59. Kruczynski, A.; Ricome, C.; Waud, W.; Hill B. T. In vivo antitumor activity of F11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts. J. Exp. Ther. Oncol., 2002, 2, 219-227.
60. Jensen, L, H.; Renodon-Corniére, A.; Nitiss, K. C. Hill, Bridget T.; Nitiss, John L.; Jensen, Peter B.; Sehested, M. A dual mechanism of action of the anticancer agent F11782 on human topoisomerase IIγ. Biochem. Pharmacol., 2003, 66, 623-631.
61. Barret, J. M.; Hill, B. T.; Olive, P. L. Characterization of DNAstrand breakage induced in V79 cells by F11782, a catalytic inhibitor of topoisomerases. Br. J. Cancer, 2000, 83, 1740-1746.
62. Barret, J. M.; Etiévant, C.; Baudouin, C.; Skov, K.; Charveron, M.; Hill, B. T. F11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells. Anticancer Res., 2002, 22, 187-192.
63. Kruczynski, A.; Barret, J. M.; van Hille, B.; Chansard, N.; Astruc, J.; Menon, Y.; Duchier, C.; Créancier, L.; Hill, B. T. Decreased Nucleotide Excision Repair Activity and Alterations of Topoisomerase IIα Are Associated with the in vivo Resistance of a P388 Leukemia Subline to F11782, a Novel Catalytic Inhibitor of Topoisomerases I and II. Clin. Cancer Res., 2004, 10, 3156-3168.
64. Kluza, J.; Mazinghien, R.; Irwin, H.; Hartley, J. A.; Bailly, C. Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with Tafluposide or Etoposide. Anti-Cancer Drugs, 2006, 17, 155-164.
65. Martinez-Vituero, C. M.; Dominguez, D. Synthesis of the antitumoral agent Batracylin and related isoindolo[1, 2-b]quinazolin-12 (10H) ones. Tethahedron Lett., 2007, 48, 1023-1026.
66. Mucci-LoRusso, P.; Polin, L.; Bissery M. C.; Valeriote, F.; Plowman, J.; Corbettv, T. H.; Luk, G. D. Activity of batracylin (NSC-320846) against solid tumors of mice. Invest. New Drugs, 1989, 7, 295-306.
67. Plowman, J.; Paull, K, D.; Atassi, G.; Harrison, S. D., Jr.; Dykes, D. J.; Kabbe, H. J.; Narayanan, V. L.; Yoder, O. C. Preclinical antitumor activity of batracylin (NSC 320846). Invest. New Drugs, 1988, 6, 147-153.
68. Luo, Y.; Ren, Y. F.; Chou, T. C.; Chen, A. Y.; Yu, C.; Liu, L. F.; Cheng, C. C. A Structure-activity relationship study of batracylin analogues. Pharm. Res., 1993, 10, 918-923.
69. Paull, K. D.; Shoemaker, R. H.; Hodes, L. Monks A; Scudiero D A; Rubinstein L; Plowman J; Boyd M R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 1989, 81, 1088-1092.
70. Monks, A.; Scudiero, D.; Skehan, Shoemaker, P. R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 1991, 83, 757-766.
71. Atassi, G.; Dumont, P.; Kabbe, H. J.; Yoder, O. A new antitumour agent, Batracylin, selected by a preclinical solid tumour model. Drugs Exp. Clin. Res., 1988, 14, 571-574.
72. Moreau, P.; Holbeck, S.; Prudhomme, M.; Sausville, E. A. Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumour cell lines. Anticancer Drugs, 2005, 16, 145-150.
73. Rao, V. A.; Agama, K.; Holbeck, S.; Pommier, Y. Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone γ-H2AX as a biomarker of DNA damage. Cancer Res., 2007, 67, 9971-9979.
74. Pourquier, P.; Pommier, Y. Topoisomerase I-mediated DNA damage. Adv. Cancer Res., 2001, 80, 189-216.
75. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Baker, M.; Liddle, C.; Bootle, D.; Kofler, B.; Laurie, D.; Denny, W. A.; Baguley, B.; Charlton, P. A. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs, 2002, 13, 15-28.
76. Stewart, A. J.; Mistry, P.; Dangerfield, W.; Bootle, D.; Baker, M.; Kofler, B.; Okiji, S.; Baguley, B. C.; Denny, W. A.; Charlton, P. A. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs, 2001, 12, 359-367.
77. Byers, S. A.; Schafer, B.; Sappal, D. S.; Brown, J.; Price, D. H. The antiproliferative agent MLN944 preferentially inhibits transcription. Mol. Cancer Ther., 2005, 4, 1260-1267.
78. Dai, J.; Punchihewa, C.; Mistry, P.; Ooi, A. T.; Yang, D. Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug. J. Biol. Chem., 2004, 279, 46096-46103.
79. Sappal, D. S.; McClendon, A. K.; Fleming, J. A.; Thoroddsen, V.; Connolly, K.; Reimer, C.; Blackman, R. K.; Bulawa, C. E.; Oshero, V. N.; Charlton, P.; Rudolph-Owen, L. A. Biological characterization of MLN944: a potent DNA binding agent. Mol. Cancer Ther., 2004, 3, 47-58.
80. Jobson, A. G.; Willmore, E.; Tilby, M. J.; Mistry, P.; Charlton, P.; Austin, C. A. Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases. Cancer Chemother. Pharmacol., 2009, 63, 889-901.
81. Lewis, L. J.; Mistry, P.; Charlton, P. A.; Thomas, H.; Coley, H. M. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944. Anticancer Drugs, 2007, 18, 139-148.
82. Lewis, L. J.; Charlton, P. A.; Mistry, P.; Thomas, H.; Coley, H. M. Cellular characterization and differentiation of XR5944 (MLN944) from XR11576 (MLN576), two novel DNA targeting agents. Proc. AACR, 2003, 44, 406
83. Verborg, W.; Thomas, H.; Bissett, D.; Waterfall, J.; Steiner, J.; Cooper, M.; Rankin, E. M. First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action. Br. J. Cancer, 2007, 97, 844-850.
84. Di Nicolantonio, F.; Knight, L. A.; Di Palma, S.; Sharma, S.; Whitehouse, P. A.; Mercer, S. J.; Charlton, P. A.; Norris, D.; Cree, I. A. Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. Anticancer Drugs, 2004, 15, 849-860.
85. Di Nicolantonio, F.; Prin, A.; Mills, L.; Knight, L. A.; Charlton, P. A.; Cree, I. A. The effect of MDR1 on the ex vivo activity of XR5944 (MLN944) and XR11576 (MLN576), two novel DNA targeting agents. Eur. J. Cancer, 2002, 38, 32.
86. de Jonge, M. J.; Kaye, S.; Verweij, J.; Brock, C.; Reade, S.; Scurr, M.; van Doorn, L.; Verheij, C.; Loos, W.; Brindley, C.; Mistry, P.; Cooper, M.; Judson, I. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. Br. J. Cancer, 2004, 91, 1459-1465.
87. Stewart, A. J.; Mistry, P.; Dangerfield, W.; Bootle, D.; Baker, M.; Kofler, B.; Okiji, S.; Baguley, B. C.; Denny, W. A.; Charlton, P. A. Antitumour activity of XR-5944, a novel and potent topoisomerase poison. Anticancer Drugs, 2001, 12, 359-367.
88. Dai, J.; Punchihewa, C.; Mistry, P.; Ooi, A. T.; Yang, D. Novel DNA bisintercalation by MLN944, a potent clinical bisphenazine anticancer drug. J. Biol. Chem., 2004, 279, 46096-46103.
89. Byers, S. A.; Schafer, B.; Sappal, D. S.; Brown, J.; Price, D. H. The antiproliferative agent MLN944 preferentially inhibits transcription. Mol. Cancer Ther., 2005, 4, 1260-1267.
90. Sappal, D. S.; McClendon, A. K.; Fleming, J. A.; Thoroddson, V.; Connolly, K.; Reimer, C.; Blackman, R. K.; Bulawa, C. E.; Osheroff, N.; Charlton, P.; Rudolph-Owen, L. A. Biological characterisation of MLN944: a potent DNA binding agent. Mol. Cancer Ther. 2004 3, 47-58.
91. Di Nicolantonio, F.; Knight, L. A.; Whitehouse, P. A.; Mercer, S. J.; Sharma, S.; Charlton, P. A.; Norris, D.; Cree, I. A. The ex vivo characterization of XR5944.14 (MLN944) against a panel of human clinical tumour samples. Mol. Cancer Ther., 2004, 3, 1631-1637.
92. Harris, S. M.; Mistry, P.; Freathy, C.; Brown, J. L.; Charlton, P. A. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Br. J. Cancer, 2005, 92, 722-728.
93. Harris, S. M.; Scott, J. A.; Brown, J. L.; Charlton, P. A.; Mistry, P. Preclinical anti-tumour activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell carcinoma. Anticancer Drugs, 2005, 16, 945-951
94. (a) Perez-Tomas, R. and Montaner, B. Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol. Histopathol., 2003, 18, 379-385.
95. (b) Perez-Tomas, R.; Montaner, B.; Llagostera, E. and Soto-Cerrato, V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochem. Pharmacol. 2003, 66, 1447-1452.
96. Songia, S.; Mortellaro, A.; Taverna, S.; Fornasiero, C.; Scheiber, E. A.; Erba, E.; Colotta, F.; Mantovani, A.; Isetta, A. M. and Golay, J. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes. J. Immunol., 1997, 158, 3987-3995.
97. D'Alessio, R.; Bargiotti, A.; Carlini, O.; Colotta, F.; Ferrari, M.; Gnocchi, P.; Isseta, A.; Mongelli, N.; Motta, P.; Rossi, A.; Rossi, M.; Tibolla, M.; Vanotti, E. Synthesis and immunosuppressive activity of novel prodigiosin derivatives. J. Med. Chem., 2000, 43, 2557-2565.
98. Boyd, M. R. The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985-1995. In Anticancer drug development guide: preclinical screening, clinical trials, and approval, B. A. Teicher, Ed. Humana Press, Totowa, NY, 1987; pp. 23-42.
99. Soto-Cerrato, V.; Llagostera, E.; Montaner, B.; Scheffer, G. L. and Perez-Tomas, R. The novel anticancer agent prodigiosin triggers mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells. Biochem. Pharmacol., 2004, 68, 1345-1352.
100. - symporter, induces apoptosis in human breast cancer cell lines. J. Cancer Res. Clin. Oncol., 2000a, 126, 191-197.
101. Montaner, B.; Navarro, S.; Pique, M.; Vilaseca, M.; Martinell, M.; Giralt, E.; Gil, J.; Perez-Tomas, R. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br. J. Pharmacol., 2000, 131, 585-593.
102. - symporter, induces apoptosis and differentiation in HL-60 cells. Int. J. Cancer, 2000b, 88, 121-128.
103. Montaner, B.; Perez-Tomas, R. Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci., 2001, 68, 2025-2036.
104. - symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology, 1999, 30, 894-902.
105. Campas, C.; Dalmau, M.; Montaner, B.; Barragan, M.; Bellosillo, B.; Colomer, D.; Pons, G.; Perez-Tomas, R. and Gil, J. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia, 2003, 17, 746-750.
106. Melvin, M. S.; Ferguson, D. C.; Lindquist, N. and Manderville, R. A. DNA binding by 4-methoxypyrrolic natural products. Preference for intercalation at AT sites by tambjamine E and prodigiosin. J. Org. Chem., 1999, 64, 6861-6869.
107. Pons, M.; Campayo, L.; Martinez-Balbas, M. A.; Azorin, F.; Navarro, P.; Giralt, E. A novel ionisable chromophore of 1, 4-bis (alkylamino)-benzo[g] phthalazine which interacts with DNA by intercalation. J. Med. Chem., 1991, 34, 82-86.
108. Bible, K. C.; Bible, R. H.; Kottke, Jr. T. J.; Svingen, P. A.; Xu, K.; Pang, Y. P.; Hadju, E.; Kaufmann, S. H. Flavopiridol binds to duplex DNA. Cancer Res., 2000, 60, 2419-2428.
109. Montaner, B.; Castillo-Ávila, W.; Martinell, M.; Öllinger, R.; Aymami, J.; Giralt, E.; Pérez-Tomás, R. DNA interaction and dual topoisomerase I and II Inhibition Properties of the anti-tumor drug prodigiosin. Toxicol. Sci., 2005, 85, 870-879.
110. Boger, D. L.; Patel, M. Total synthesis of prodigiosin, prodigiosene, and desmethoxyprodigiosin: Diels-Alder reactions of hetero cyclic azadienes and development of an effective palladium (II) - promoted 2, 2'-bipyrrole coupling procedure. J. Org. Chem., 1988, 53, 1405-1415.
111. Melvin, M. S.; Tomlinson, J. T.; Saluta, G. R.; Kucera, G. L.; Lindquist, N.; Manderville, R. A. Double-strand DNA cleavage by copper prodigiosin. J. Am. Chem. Soc., 2000, 122, 6333-6334.
112. Aggarwal, B. B.; Sundaram, C.; Malani N.; Ichikawa H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol., 2007, 595, 1-75.
113. Duvoix, A.; Blasius, R.; Delhalle, S.; Schnekenburger, M.; Morceau, F.; Henry, E.; Dicato, M.; Diederich, M. Chemopreventive and therapeutic effects of curcumin. Cancer Lett., 2005, 223, 181-190.
114. Aggarwal, B. B.; Kumar, A.; Bharti, A. C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res., 2003, 23, 363-398.
115. Sharma, R. A.; Gescher, A. J.; Steward, W. P. Curcumin: The story so far. Eur. J. Cancer, 2005, 41, 1955-1968.
116. Johnson, J. J.; Mukhtar, H. Curcumin for chemoprevention of colon cancer. Cancer Lett., 2007, 255, 170-181.
117. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55, 74-108.
118. Cheng, A. L.; Hsu, C. H.; Lin, J. K.; Hsu, M. M.; Ho, Y. F.; Shen, T. S.; Ko, J. Y.; Lin, J. T.; Lin, B. R.; Ming-Shiang, W.; Yu, H. S.; Jee, S. H.; Chen, G. S.; Chen, T. M.; Chen, C. A.; Lai, M. K.; Pu, Y. S.; Pan, M. H.; Wang, Y. J.; Tsai, C. C.; Hsieh, C. Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21, 2895-2900.
119. Karunagaran, D.; Rashmi, R.; Kumar, T. R. Induction of apoptosis by curcumin and its implications for cancer therapy. Curr. Cancer Drug Targets, 2005, 5, 117-129.
120. Ramachandran, C.; You, W. Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin. Breast Cancer Res. Treat., 1999, 54, 269-278.
121. Jiang, M. C.; Yang-Yen, H. F.; Yen, J. J.; Lin, J. K. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr. Cancer, 1996, 26, 111-120.
122. Syng-Ai, C.; Kumari, A. L.; Khar, A. Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol. Cancer Ther., 2004, 3, 1101-1108.
123. Everett, P. C.; Meyers, J. A.; Makkinje, A.; Rabbi, M.; Lerner, A. Preclinical assessment of curcumin as a potential therapy for BCLL. Am. J. Hematol., 2007, 82, 23-30.
124. Choudhuri, T.; Pal, S.; Das, T.; Sa, G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J. Biol. Chem., 2005, 280, 20059-20068.
125. Chendil, D.; Ranga, R. S.; Meigooni, D.; Sathishkumar, S.; Ahmed, M. M. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene, 2004, 23, 1599-1607.
126. Bava, S. V.; Puliappadamba, V. T.; Deepti, A.; Nair, A.; Karunagaran, D.; Anto, R. J. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J. Biol. Chem., 2005, 280, 6301-6308.
127. Li, M.; Zhang, Z.; Hill, D. L.; Wang, H.; Zhang, R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res., 2007, 67, 1988-1996.
128. Lin, J. K. Molecular targets of curcumin. Adv. Exp. Med. Biol., 2007, 595, 227-243.
129. Chih-Li, L.; Jen-Kun, L. Curcumin: a Potential Cancer Chemopreventive Agent through Suppressing NF-κB Signaling. J. Cancer Mol., 2008, 4 (1), 11-16.
130. Martin-Cordero, C.; López-Lázaro, M.; Galvez, M.; Ayuso, M. J. Curcumin as a DNA topoisomerase II poison. J. Enzyme Inhib. Med. Chem., 2003, 18, 505-509.
131. López-Lázaro, M.; Willmore, E.; Jobson, A.; Gilroy, K. L.; Curtis, H.; Padget, K.; Austin, C. A. Curcumin Induces High Levels of Topoisomerase I-and II-DNA Complexes in K562 Leukemia Cells J. Nat. Prod., 2007, 70 (12), 1884-1888.
132. Dhandapani, K. M.; Mahesh, V. B.; Brann, D. W. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J. Neurochem., 2007, 102, 522-538.
133. Willmore, E.; Errington, F.; Tilby, M. J.; Austin, C. A. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem. Pharmacol., 2002, 63, 1807-1815.
134. López-Lázaro, M.; Willmore, E.; Austin, C. A. Cells lacking DNA topoisomerase II beta are resistant to genistein. J. Nat. Prod., 2007, 70, 763-767.
135. Sordet, O.; Goldman, A.; Pommier, Y. Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes. Mol. Cancer Ther., 2006, 5, 3139-3144.
136. Ireson, C. R.; Jones, D. J.; Orr, S.; Coughtrie, M. W.; Boocock, D. J.; Williams, M. L.; Farmer, P. B.; Steward, W. P.; Gescher, A. J. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev., 2002, 11, 105-111.
137. Li, Y.; Fang, H.; Xu, W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev. Med. Chem., 2007, 7, 663-678.
138. Hickok, L. G. and Anway, J. C., A morphological and chemical analysis of geographical variation in Tilia L. of eastern North America. Brittonia, 1972, 24, 2-8.
139. Yu, Y. P.; Kang, S. S. and Kim, C. M., A study on the chemical constituents of Tilia koreana Nakai. Kor. J. Pharmacogn., 1990, 21, 265-269.
140. Kim, C. M.; Kang, S. S.; Park, Y. S.; Kim, E. Y. Studies on the chemical constituents of Tilia plants in Korea (I). On the chemical constituents of the stem-bark of Tilia mandsurica. Kor. J. Pharmacogn., 1988, 19, 174-176.
141. Pietta, P. High-performance liquid chromatography and micellar electrokinetic chromatography of flavonol glycosides from Tilia. J. Chromatogr., 1993, 638, 357-361.
142. Toker, G.; Küpeli, E.; Memisoolu, M., and Yesilada, E., Flavonoids with antinociceptive and anti-inflammatory activities from the leaves of Tilia argentea (silver linden). J. Ethnopharmacol., 2004, 95, 393-397.
143. Viola, H.; Wolfman, C.; Destein, M. L.; Wasowski, C.; Pena, C.; Medina, J. H.; Paladine, A. C. Isolation of pharmacologically active benzodiazepine receptor ligands from Tilia tomentosa (Tiliceae). J. Ethnopharmacol., 1994, 44, 47-53.
144. Matsuda, H.; Ninomiya, K.; Shimoda, H.; Yoshikawa, M. Hepatoprotective principles from the flowers of Tilia argentea (Linden): Structure requirements of tiliroside and mechanism of action. Bioorg. Med. Chem., 2002, 10, 707-712.
145. Choi, J. Y.; Seo, C. S.; Zheng, M. S.; Lee, C. S.; Son, J. K. Topoisomerase I and II inhibitory constituents from the bark of Tilia amurensis. Arch. Pharm. Res., 2008, 31, 1413-1418.
146. (a) Kanai, Y.; Ishiyama, D.; Senda, H.; Iwatani, W.; Takahashi, H.; Konno, H.; Tokumasu, S.; Kanazawa, S. Novel human topoisomerase I inhibitors, topopyrones A, B, C and D. I. Producing strain, fermentation, isolation, physico-chemical properties and biological activity. J. Antibiot. (Tokyo), 2000, 53, 863-872.
147. (b) Ishiyama, D.; Kanai, Y.; Senda, H.; Iwatani, W.; Takahashi, H.; Konno, H.; Kanazawa, S. Novel human topoisomerase I inhibitors, topopyrones A, B, C and D. II. Structure elucidation. J. Antibiot. (Tokyo), 2000, 53, 873-878.
148. (a) Tan, J. S.; Ciufolini, M. A. Total synthesis of topopyrones B and D. Org. Lett. 2006, 8, 4771-4774.
149. (b) Gattinoni, S.; Merlini, L.; Dallavelle, S. First total synthesis of topopyrone C. Tetrahedron Lett., 2007, 48, 1049-1051.
150. (c) Elban, M. A.; Hecht, S. M. Total synthesis of the topopyrones: a new class of topoisomerase I poisons. J. Org. Chem., 2008, 73, 785-793.
151. Sun, D.; Hansen, M.; Clement, J. J.; Hurley, L. H. Structure of the altromycin B (N7-guanine)-DNA adduct. A proposed prototypic DNA-adduct structure for the pluramycin antitumor antibiotics. Biochemistry 1993, 32, 8068-8074.
152. Khan, Q. A.; Elban, M. A.; Hecht, S. M. The Topopyrones Poison Human DNA Topoisomerases I and II. J. Am. Chem. Soc., 2008, 130, 12888-12889.
153. Hecht, S. M.; Khan, Q. A.; Maini, R.; Leiris, S. Topopyrones: Dual topoisomerase inhibitors. 2010, Patent PCT/US2009/050081.
154. Galati, G.; O'Brien, P. J. Potential toxicity of flavonoids and other dietary phenolics: significance of their chemopreventive and anticancer properties. Free Radic. Biol. Med., 2004, 37, 287-303.
155. Rietjens, I. M.; Boersma, M. G.; van der Woude, H.; Jeurissen, S. M. F.; Schutte, M. E.; Alink, G. M. Flavonoids and alkenylbenzenes: Mechanisms of mutagenic action and carcinogenic risk. Mutat. Res., 2005, 574, 124-138.
156. López-Lázaro, M.; Martin-Cordero, C.; Toro, M. V.; Ayuso, M. J. Flavonoids as DNA topoisomerase I poisons. J. Enzyme Inhib. Med. Chem., 2002, 17, 25-29.
157. Bandele, O. J.; Osheroff, N. Bioflavonoids as poisons of human topoisomerase IIalpha and IIbeta. Biochemistry, 2007, 46, 6097-6108.
158. López-Lázaro, M.; Willmore, E.; Austin, C. A. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat. Res., 2010, 696, 41-47.
159. Liu, L. F. DNA topoisomerases poisons as antitumor drugs. Annu. Rev. Biochem., 1989, 58, 351-375.
160. Wang, B.; Perchellet, E.; Wang, Y.; Tamura, M.; Hua, D. H.; Perchellet, J. P. H. Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities. Anti-Cancer Drugs, 2003, 14, 503-514.
161. Perchellet, E. M.; Magill, M. J.; Huang, X.; Brantis, C. E.; Hua, D. H.; Perchellet, J. P. Triptycenes: a novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range in vitro. Anticancer Drugs, 1999, 10, 749-766.
162. Perchellet, E. M.; Sperfslage, B. J.; Wang, Y.; Huang, X.; Tamura, M.;
163. Wang, B.; Wu, M.; Perchellet, E. M.; McIlvain, Corbin J.; Sperfslage, Bonnie J.; Huang, X.; Tamura, M.; Stephany, H. A.; Hua, D H.; Perchellet, J. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines. Int. J. Oncol., 2001, 19, 1169-1178.
164. Hua, D. H.; Tamura, M.; Huang, X.; Stephany, H A.; Helfrich, B A.; Perchellet, E M.; Sperfslage, B J.; Perchellet, J.; Jiang, S.; Kyle, D E.; Chiang, P K. Syntheses and bioactivities of substituted 9, 10-dihydro-9, 10-[1, 2]benzenoanthracene-1, 4, 5, 8-tetraones. Unusual rea-ctivities with amines. J. Org. Chem., 2002, 67, 2907-2912.
165. Demarquay, D.; Huchet, M.; Coulomb, H.; Lesueur-Ginot, L.; Lavergne, O.; Camara, J.; Kasprzyk, P. G.; Prévost, G.; Bigg, D. C. H. BN80927: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer Res., 2004, 64, 4942-4949.
166. Lavergne, O.; Demarquay, D.; Bailly, C.; Lanco, C.; Rolland, A.; Huchet, M.; Coulomb, H.; Muller, N.; Baroggi, N.; Camara, J.; Le Breton, C.; Manginot, E.; Cazaux, J.; Bigg, D C. H. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J. Med. Chem., 2000, 43 (11), 2285-2289.
167. Demarquay, D.; Coulomb, H.; Huchet, M.; Lesueur-Ginot, L.; Camara, J.; Lavergne, O.; Bigg, D. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor. Ann. N. Y. Acad. Sci., 2000, 922, 301-302.
168. Huchet, M.; Demarquay, D.; Coulomb, H.; Kasprzyk, P.; Carlson, M.; Lauer, J.; Lavergne, O.; Bigg, D. The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann. N. Y. Acad. Sci., 2000, 922, 303-305.
169. Lavergne, O.; Harnett, J.; Rolland, A.; Lanco, C.; Lesueur-Ginot, L.; Demarquay, D.; Huchet, M.; Coulomb, H.; Bigg, D. C. H. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Bioorg. Med. Chem. Lett., 1999, 9 (17), 2599-2602.
170. Mo, Y. Y.; Beck, W. T. DNA damage signals induction of fas ligand in tumor cells. Mol. Pharmacol., 1999, 55 (2), 216-222.
171. Taniguchi, K.; Kohno, K.; Kawanami, K.; Wada, M.; Kanematsu, T.; Kuwano, M. Drug induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res., 1996, 56 (10), 2348-2354.
172. Utsugi, T.; Aoyagi, K.; Asao, T.; Okazaki, S.; Aoyagi, Y.; Sano, M.; Wierzba, K.; Yamada, Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn. J. Cancer Res., 1997, 88 (10), 992-1002.
173. Padget, K.; Stewart, A.; Charlton, P.; Tilby, M. J.; Austin, C. A. An Investigation into the Formation of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino) ethylamino]-3-hydroxy-7H- indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) Stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem. Pharmacol., 2000, 60, 817-821.
174. Bases, R. E.; Mendez, F. Topoisomerase inhibition by lucanthone, an adjuvant in radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37 (5), 1133-1137.
175. Lowe, G.; Droz, A. S.; Park, J. J.; Weaver, G. W. The design and synthesis of bis[4'-azido-2, 2':6', 2"-terpyridine]platinum (II) complexes with rigid and extended linkers for studying the topology of DNA by photoaffinity labeling. Bioorg. Chem., 1999, 27, 477.
176. Carter, P. J.; Cheng, C. C.; Thorp, H. H. Oxidation of DNA and RNA by oxoruthenium (IV) metallointercalators: Visualizing the recognition properties of dipyridophenazine by high-resolution electrophoresis. J. Am. Chem. Soc., 1998, 120, 632.
177. Zhao, L. X.; Kim, T. S.; Ahn, S. H.; Kim, T. H.; Kim, E. K.; Cho, W. J.; Choi, H.; Lee, C. S.; Kim, J. A.; Jeong, T. C.; Change, C. J.; Lee, E. S. Synthesis, topoisomerase I inhibition and antitumor cytotoxicity of 2, 2':6', 2"-, 2, 2':6', 3"-and 2, 2':6', 4"-Terpyridine derivatives. Bioorg. Med. Chem. Lett., 2001, 11, 2659.
178. Zhao, L. X.; Moon, Y. S.; Basnet, A.; Kim, E. K.; Cho, W. J.; Jahng, Y.; Park, J. G.; Jeong, T. C.; Cho, W. J.; Choi, S. U.; Lee, C. O.; Lee, S. Y.; Lee, C. S.; Lee, E. S. Synthesis, topoisomerase I inhibition and structure-activity relationship study of 2, 4, 6-trisubstituted pyridine derivatives. Bioorg. Med. Chem. Lett., 2004, 14, 1333.
179. Kim, D. S. H. L.; Ashendel, C. L.; Zhou, Q.; Chang, C. T.; Lee, E.-S.; Chang, C. J. Novel protein kinase c inhibitors: alphaterthiophene derivatives. Bioorg. Med. Chem. Lett., 1998, 8, 2695.
180. Basnet, A.; Thapa, P.; Karki, R.; Na, Y.; Jahng, Y.; Jeong, BS.; Jeong, TC.; Lee, CS. and Lee, ES. 2, 4, 6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Bioorg. Med. Chem., 2007, 15, 4351-4359.
181. Dalla Via, L.; Marciani Magno, S.; Gia, O.; Marini, A. M.; Da Settimo, F.; Salerno, S.; La Motta, C.; Simorini, F.; Taliani, S.; Lavecchia, A., Di Giovanni, C.; Brancato, G.; Barone, V.; Novellino, E. Benzothiopyranoindole- based antiproliferative agents: Synthesis, Cytotoxicity, Nucleic acids Interaction and Topoisomerases Inhibition Properties. J. Med. Chem., 2009, 52, 5429-5441.